NCT00483717View on ClinicalTrials.gov

Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine

PHASE2CompletedINTERVENTIONAL

Enrollment

173

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Migraine

Interventions

DRUG

Ketorolac tromethamine

31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)

DRUG

Placebo

Intranasal (IN) placebo

Trial Locations (1)

80802

Volker Pfaffenrath, Munich

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Egalet Ltd

INDUSTRY